Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Brain Metastases: Chemotherapy

  • Neuro-oncology (M Gilbert, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Although systemic therapy is the primary therapeutic modality for disseminated cancer, it plays a limited role in the treatment of brain metastases (BM). This review discusses the blood–brain barrier (BBB), interactions of systemic therapy with supportive care agents used in BM patients, the role of primary tumor sensitivity in the treatment of BM, and unique issues related to the specific primary tumor histologies. The specialized physiology of the brain vasculature that forms the BBB may preclude large and/or water-soluble systemic agents from reaching BM. Once metastases grow larger than 1–2 mm, there is preclinical and clinical evidence that the BBB is at least partially disrupted. Thus, the best treatment strategy in established BM may be to use an agent that is effective against the primary tumor regardless of its apparent BBB permeability. The use of anticonvulsants and corticosteroids must be carefully considered as they can decrease the effectiveness of systemic anti-tumor therapy. Despite the absence of level I data to routinely recommend the use of systemic therapy for solid tumor BM, these treatments should be considered in patients with good performance status and multiple, small metastases, especially if the primary tumor is chemosensitive. The systemic treatment of BM will continue to evolve as effective small-molecule inhibitors are developed and treatment regimens for each specific primary tumor are optimized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):71–83.

    Article  PubMed  Google Scholar 

  2. DeAngelis LM, Posner JB, Posner JB. Neurologic complications of cancer. 2nd ed. Oxford, New York: Oxford University Press; 2009. xv, 634 p.

    Google Scholar 

  3. Eichler AF, Chung E, Kodack DP, et al. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344–56.

    PubMed  CAS  Google Scholar 

  4. Gerstner ER, Fine RL. Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25(16):2306–12.

    Article  PubMed  Google Scholar 

  5. Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol. 2011;21(2):107–12.

    Article  PubMed  Google Scholar 

  6. Fine RL, Chen J, Balmaceda C, et al. Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res. 2006;12(19):5770–6.

    Article  PubMed  CAS  Google Scholar 

  7. Kamar FG, Posner JB. Brain metastases. Semin Neurol. 2004;30(3):217–35.

    Article  Google Scholar 

  8. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30(8):1385–407.

    Article  PubMed  CAS  Google Scholar 

  9. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology. 2006;67(12 Suppl 4):S10–3.

    PubMed  Google Scholar 

  10. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.

    Article  PubMed  Google Scholar 

  11. Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78(8):1781–8.

    Article  PubMed  CAS  Google Scholar 

  12. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–705.

    Article  PubMed  Google Scholar 

  13. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23(25):6207–19.

    Article  PubMed  CAS  Google Scholar 

  14. Forouzannia A, Richards GM, Khuntia D, et al. Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Rev Anticancer Ther. 2007;7(6):785–94.

    Article  PubMed  CAS  Google Scholar 

  15. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1069–76.

    Article  PubMed  CAS  Google Scholar 

  16. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

    Article  PubMed  CAS  Google Scholar 

  17. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006;12(15):4738–46.

    Article  PubMed  CAS  Google Scholar 

  18. Kil WJ, Cerna D, Burgan WE, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res. 2008;14(3):931–8.

    Article  PubMed  CAS  Google Scholar 

  19. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20(17):3644–50.

    Article  PubMed  CAS  Google Scholar 

  20. Dardoufas CMA, Skareleas C, et al. Concomitant temozolomide and radiotherapy followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumors. Proc Am Soc Clin Oncol. 2001;20:75b.

    Google Scholar 

  21. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005;61(1):185–91.

    Article  PubMed  CAS  Google Scholar 

  22. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27(31):5255–61.

    Article  PubMed  CAS  Google Scholar 

  23. De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol. 2010;100(3):443–7.

    Article  PubMed  Google Scholar 

  24. Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011;6(7):1287–9.

    Article  PubMed  Google Scholar 

  25. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624–31.

    Article  PubMed  CAS  Google Scholar 

  26. Grommes C, Oxnard GR, Kris MG et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011.

  27. Barlesi F, Gervais R, Lena H et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07–01). Ann Oncol 2011.

  28. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608–17.

    Article  PubMed  Google Scholar 

  29. Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother. 2010;11(7):1089–100.

    Article  PubMed  CAS  Google Scholar 

  30. Boogerd W, Dalesio O, Bais EM, et al. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69(4):972–80.

    Article  PubMed  CAS  Google Scholar 

  31. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 1986;58(4):832–9.

    Article  PubMed  CAS  Google Scholar 

  32. Ekenel M, Hormigo AM, Peak S, et al. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007;85(2):223–7.

    Article  PubMed  CAS  Google Scholar 

  33. Fabi A, Vidiri A, Ferretti G, et al. Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow? Cancer Invest. 2006;24(4):466–8.

    Article  PubMed  CAS  Google Scholar 

  34. Wang ML, Yung WK, Royce ME, et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001;24(4):421–4.

    Article  PubMed  CAS  Google Scholar 

  35. Lien EA, Wester K, Lonning PE, et al. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer. 1991;63(4):641–5.

    Article  PubMed  CAS  Google Scholar 

  36. Pors H, von Eyben FE, Sorensen OS, et al. Longterm remission of multiple brain metastases with tamoxifen. J Neurooncol. 1991;10(2):173–7.

    Article  PubMed  CAS  Google Scholar 

  37. Salvati M, Cervoni L, Innocenzi G, et al. Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori. 1993;79(5):359–62.

    PubMed  CAS  Google Scholar 

  38. Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J Neurooncol. 1995;24(3):299–301.

    Article  PubMed  CAS  Google Scholar 

  39. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49(5):650–5.

    Article  PubMed  CAS  Google Scholar 

  40. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13(6):1648–55.

    Article  PubMed  CAS  Google Scholar 

  41. Fuchs IB, Loebbecke M, Buhler H, et al. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol. 2002;20(19):4130–3.

    Article  PubMed  Google Scholar 

  42. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.

    Article  PubMed  CAS  Google Scholar 

  43. Lin NU, Eierman W, Greil R et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011.

  44. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25(6):601–13.

    Article  PubMed  CAS  Google Scholar 

  45. Lawrence DPHO, McDermott DF, et al. Phase II trial of ipilimumamb monotherapy in melanoma patients with brain metastases. J Clin Oncol. 2010;28(suppl):7s8523.

    Google Scholar 

  46. Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011;117(3):501–9.

    Article  PubMed  CAS  Google Scholar 

  47. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272–80.

    Article  PubMed  CAS  Google Scholar 

  48. Hill Jr KL, Lipson AC, Sheehan JM. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J Neurosurg. 2009;111(3):497–503.

    Article  PubMed  Google Scholar 

  49. Kelly PJ, Weiss SE, Sher DJ, et al. Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. J Clin Oncol. 2010;28(25):e433–5.

    Article  PubMed  Google Scholar 

Download references

Disclosure

S. A. Grimm: consultant to Genentech.

Author information

Authors and Affiliations

  1. Department of Neurology, Northwestern University, Feinberg School of Medicine, 710 N. Lake Shore Drive, Chicago, IL, 60611, USA

    Sean A. Grimm

Authors
  1. Sean A. Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean A. Grimm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grimm, S.A. Treatment of Brain Metastases: Chemotherapy. Curr Oncol Rep 14, 85–90 (2012). https://doi.org/10.1007/s11912-011-0211-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-011-0211-y

Keywords

Search

Navigation